Hormone therapy for prostate cancer works for a wide range of time depending on the stage of the disease, from many years in localized cases to a median of roughly two years in men with metastatic cancer at diagnosis. The answer depends heavily on whether the cancer has spread, how aggressive it is, and whether hormone therapy is combined with other treatments.
Why the Timeline Varies So Much
Hormone therapy, also called androgen deprivation therapy (ADT), works by cutting off the testosterone that prostate cancer cells need to grow. How long that strategy keeps the cancer in check is tied directly to how advanced the disease is when treatment begins. In a large study tracking men who started combined hormone therapy, the median time before the cancer stopped responding was about 140 months (nearly 12 years) across all patients. But that number masks enormous variation. Men who already had metastatic disease at diagnosis saw the cancer become resistant after a median of just 26.6 months. Men without metastases at the start often went many years before resistance developed, and in lower-risk groups the median wasn’t even reached during the study period.
Localized Cancer Paired With Radiation
For cancer that hasn’t spread beyond the prostate, hormone therapy is typically used alongside radiation rather than on its own. Here, the question isn’t how long the therapy “works” so much as how long you need to take it for the best outcome. Current guidelines recommend 18 to 36 months of ADT for high-risk localized disease, though a recent meta-analysis found that the measurable benefits of longer treatment start to plateau around 9 to 12 months, depending on the specific outcome measured. This has raised questions about whether some men could safely receive shorter courses.
A Spanish study of 355 men illustrates the difference risk level makes. Men with high-risk localized cancer who received 24 months of hormone therapy had a 78.5% survival rate at 10 years, compared to 67% for those who received only four months. But among men with intermediate-risk cancer, the duration barely mattered. After 10 years, none of the intermediate-risk patients had died from prostate cancer regardless of whether they took hormone therapy for four months or 24 months. Men with low-risk prostate cancer generally don’t receive hormone therapy at all.
Metastatic Hormone-Sensitive Cancer
When prostate cancer has already spread to bones or other organs, hormone therapy remains the backbone of treatment, but the window of effectiveness is shorter. The median time to resistance in men with metastatic disease at diagnosis is roughly 20 to 27 months. After that, the cancer adapts and begins growing again despite very low testosterone levels, a state called castration-resistant prostate cancer.
Combining ADT with newer drugs has extended that window. In a major trial, men who received ADT alone saw their cancer progress at a median of 19.5 months, while those given a second-generation anti-androgen alongside ADT had not yet reached median progression at the time of interim analysis. This combination approach has become standard for many men with metastatic disease, pushing the effective duration of hormone-based treatment well beyond what ADT alone achieves.
How Resistance Develops
Prostate cancer cells eventually find ways to grow without normal levels of testosterone. The most important mechanism involves changes to the testosterone receptor on the surface of cancer cells. Under the pressure of prolonged hormone therapy, some cancer cells produce shortened versions of this receptor that are permanently switched “on,” no longer needing testosterone to activate them. One particular variant, called AR-V7, shows up at much higher levels in treatment-resistant cancers than in cancers that still respond to therapy. Its presence in a patient’s blood is strongly linked to resistance to the most common second-line hormone drugs.
This is a key reason why adding treatments isn’t always a solution. The shortened receptors that drive resistance are missing the exact part of the protein that current anti-androgen drugs are designed to target. Once the cancer relies on these altered receptors, therapies aimed at blocking testosterone signaling lose their grip, and different treatment strategies become necessary.
PSA Levels as an Early Signal
One of the strongest predictors of how long hormone therapy will keep working is how far your PSA drops in the first several months. The lowest point your PSA reaches after starting treatment, called the nadir, typically arrives around eight months in. Men whose PSA drops below 0.2 ng/mL tend to have much longer responses than those whose PSA only falls to moderate levels.
In one study, the nadir PSA was the single most accurate predictor of whether a man would develop treatment-resistant cancer within two years, with 86% accuracy. The critical threshold was around 1.1 ng/mL: men whose PSA didn’t fall below that level had substantially higher odds of earlier resistance. If your PSA drops deeply and stays low, that’s a strong signal the therapy is working well and may continue working for a longer period.
Continuous Versus Intermittent Treatment
Because hormone therapy carries significant side effects, including hot flashes, bone loss, fatigue, weight gain, and sexual dysfunction, some men and their doctors consider an intermittent schedule. In this approach, you take hormone therapy until your PSA drops to a low level, then stop until it rises again. The appeal is clear: breaks from treatment can improve quality of life, particularly erectile function and mental health.
A large trial of over 1,500 men with metastatic disease compared the two approaches over nearly 10 years of follow-up. Median survival was 5.8 years with continuous therapy and 5.1 years with intermittent therapy. The study couldn’t confirm that intermittent treatment was equivalent to continuous treatment. Quality-of-life improvements with the intermittent approach were real but modest, and 78% of men in the intermittent group had restarted therapy by 15 months. For metastatic disease, continuous therapy remains the more common recommendation, though intermittent schedules are sometimes used in non-metastatic settings where the stakes of a brief gap are lower.
What the Numbers Mean in Practice
If you have localized, intermediate-risk prostate cancer being treated with radiation, even a short course of hormone therapy (four to six months) may be all you need, and the cancer may never return. If you have high-risk localized disease, a longer course of 18 to 24 months paired with radiation offers a meaningful survival benefit. For metastatic disease, expect hormone therapy to be effective for roughly two to three years on its own, potentially longer with combination treatments, before the cancer adapts and new strategies are needed.
Your PSA trajectory in the first several months is the most useful early indicator of how your body is responding. A deep, sustained PSA drop signals a longer effective window, while a PSA that doesn’t fall below 1.1 ng/mL suggests the cancer may develop resistance sooner.